ACLX
NASDAQ HealthcareArcellx, Inc. - Common Stock
Biotechnology
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
�� 市场数据
| 价格 | $115.05 |
|---|---|
| 成交量 | 475,563 |
| 市值 | 6.73B |
| 贝塔系数 | 0.250 |
| RSI（14日） | 78.6 超买 |
| 200日均线 | $82.05 |
| 50日均线 | $104.27 |
| 52周最高 | $115.13 |
| 52周最低 | $47.86 |
| Forward P/E | -66.42 |
| Price / Book | 16.56 |
🎯 投资策略评分
ACLX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (68/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (8/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ACLX in your text
粘贴任何文章、记录或帖子 — 工具将提取 ACLX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.